CLAIMS

1. A compound which is:



or



or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 which is:



or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

4. A compound according to and as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from: cancer, cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic

syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis, cirrhosisbeta haemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia.

5. Use of a compound according to and as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of a disease selected from: cancer, cervical intraepithelial neoplasia, monoclonal gammapathy of unknown significance (MGUS), myelodysplastic syndrome, aplastic anemia, cervical lesions, skin nevi (pre-melanoma), prostatic intraepithleial (intraductal) neoplasia (PIN), Ductal Carcinoma in situ (DCIS), colon polyps and severe hepatitis, cirrhosisbeta haemoglobinopathy disordes, sickle cell disease, sickle cell anemia, and beta thalassemia.

6. The use according to claim 5 wherein said cancer is selected from: brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, breast, colon, head and neck, kidney, lung, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma and thyroid.

7. Use of a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or lessening the severity of cancer.

8. A compound according to claim 1 or claim 2 or a pharmaceutically acceptable salt thereof for use in the inhibition of DNMT1 activity in a mammal in need thereof.

9. Use of a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered with at least one anti-neoplastic agent.

10. The use claim 9, wherein the at least one anti-neoplastic agent is selected from the group consisting of: anti-microtubule agents, platinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis, inhibitors, immunotherapeutic agents, proapoptotic agents, cell cycle signaling inhibitors, proteasome inhibitors, inhibitors of cancer metabolism, anti-PD-L1 agents, PD-1 antagonist, immuno-modulators, STING modulating compounds, CD39 inhibitors, A2a and A2a adenosine antagonists, TLR4 antagonists, antibodies to ICOS, and antibodies to OX40.

11. A pharmaceutical combination comprising:

a) a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof; and

b) at least one anti-neoplastic agent.

12. A pharmaceutical combination as claimed in claim 11 for use in the treatment of cancer.

13. The use according to claim 5 wherein said cancer is selected from: breast cancer, inflammatory breast cancer, ductal carcinoma, lobular carcinoma, colon cancer, pancreatic cancer, insulinomas, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, skin cancer, melanoma, metastatic melanoma, lung cancer, small cell lung cancer, non-small cell lung cancer, squamous cell carcinoma, adenocarcinoma, large cell carcinoma, brain (gliomas), glioblastomas, astrocytomas, glioblastoma multiforme, Bannayan-Zonana syndrome, Cowden disease, Lhermitte-Duclos disease, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, head and neck, kidney, liver, melanoma, ovarian, pancreatic, adenocarcinoma, ductal adenocarcinoma, adenosquamous carcinoma, acinar cell carcinoma, glucagonoma, insulinoma, prostate, sarcoma, osteosarcoma, giant cell tumor of bone, thyroid,

lymphoblastic T cell leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, hairy-cell leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic neutrophilic leukemia, acute lymphoblastic T cell leukemia, plasmacytoma, Immunoblastic large cell leukemia, mantle cell leukemia, multiple myeloma, megakaryoblastic leukemia, multiple myeloma, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia,

malignant lymphoma, hodgkins lymphoma, non-hodgkins lymphoma, lymphoblastic T cell lymphoma, Burkitt’s lymphoma, follicular lymphoma,

neuroblastoma, bladder cancer, urothelial cancer, vulval cancer, cervical cancer, endometrial cancer, renal cancer, mesothelioma, esophageal cancer, salivary gland cancer, hepatocellular cancer, gastric cancer, nasopharangeal cancer, buccal cancer, cancer of the mouth, GIST (gastrointestinal stromal tumor), neuroendocrine cancers and testicular cancer.

14. A pharmaceutical combination comprising:

a) a compound as described in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof; and

b) at least one agent useful for treating beta haemoglobinopathies.

15. A pharmaceutical combination as claimed in claim 14 for use in the treatment of sickle cell disease.

16. A pharmaceutical combination as claimed in claim 14 for use in the treatment of sickle cell anemia.

17. A pharmaceutical combination as claimed in claim 14 for use in the treatment of beta-thalassemia.

18. A pharmaceutical composition comprising from 0.5 to 1,000 mg of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 or claim 2, and from 0.5 to 1,000 mg of a pharmaceutically acceptable excipient.